Publication | Open Access
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma
52
Citations
29
References
2021
Year
IGV-001 was well tolerated, PFS compared favorably with SOC, and evidence suggested an immune-mediated mechanism (ClinicalTrials.gov: NCT02507583).
| Year | Citations | |
|---|---|---|
Page 1
Page 1